ScholarIQanswers from OpenAlex & ORCID
Jie Wang
ResearcherPublications, citations & collaboration network
Jie Wang is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Jie Wang have?
ScholarIQindexed works
Jie Wang has 630 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Jie Wang have?
ScholarIQcitation count
Jie Wang has 18,661 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Jie Wang?
ScholarIQh-index
Jie Wang has an h-index of 58 in OpenAlex.
What is the i10-index of Jie Wang?
ScholarIQi10-index
Jie Wang has an i10-index of 239 in OpenAlex.
What is the ORCID of Jie Wang?
ScholarIQorcid
The ORCID for Jie Wang is on the source record.
What is the OpenAlex record for Jie Wang?
ScholarIQopenalex
The OpenAlex for Jie Wang is on the source record.
What are the most-cited papers on Jie Wang?
ScholarIQmost cited works
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou, Yi‐Long Wu, Gongyan Chen, Jifeng Feng, Xiao-Qing Liu, Changli Wang, Shucai Zhang, Jie Wang, Songwen Zhou, Shengxiang Ren, Shun Lü, Li Zhang, Chengping Hu, Chunhong Hu, Yi Luo, Lei Chen, Ming Ye, Jianan Huang, Xiuyi Zhi, Yiping Zhang, Qingyu Xiu, Jun Ma, L Zhang, Changxuan You
Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC
Shugeng Gao, Ning Li, Shun‐Yu Gao, Qi Xue, Jianming Ying, Shuhang Wang, Xiuli Tao, Jun Zhao, Yousheng Mao, Bing Wang, Kang Shao, Wendong Lei, Dali Wang, Fang Lv, Liang Zhao, Fan Zhang, Ziran Zhao, Kai Su, Fengwei Tan, Yibo Gao, Nan Sun, Dawei Wu, Yue Yu, Yun Ling, Zhijie Wang, Chunjian Duan, Wei Tang, Lei Zhang, Shun He, Ning Wu, Jie Wang, Jie He
Gefitinib plus chemotherapy versus placebo plus chemotherapy in EGFR-mutation-positive non-small-cell lung cancer after progression on first-line gefitinib (IMPRESS): a phase 3 randomised trial
Jean‐Charles Soria, Yi‐Long Wu, Kazuhiko Nakagawa, Sang-We Kim, Jin-Ji Yang, Myung‐Ju Ahn, Jie Wang, James Chih‐Hsin Yang, You Lü, Shinji Atagi, Santiago Ponce, Ki Hyeong Lee, Yunpeng Liu, Kiyotaka Yoh, Jianying Zhou, Xiaojin Shi, Alan Webster, Haiyi Jiang, Tony Mok
Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as First-line Treatment for Advanced Squamous Non–Small-Cell Lung Cancer
Jie Wang, Shun Lü, Xinmin Yu, Yanping Hu, Yuping Sun, Zhijie Wang, Jun Zhao, Yan Yu, Chunhong Hu, Kunyu Yang, Guosheng Feng, Kejing Ying, Wu Zhuang, Jianying Zhou, Jingxun Wu, Shiang Jiin Leaw, Jing Zhang, Xiao Lin, Liang Liang, Nong Yang
Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non–Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial
Roy S. Herbst, Yi‐Long Wu, Thomas John, Christian Grohé, Margarita Majem, Jie Wang, Terufumi Kato, Jonathan W. Goldman, К. К. Лактионов, Sang‐We Kim, Chong‐Jen Yu, Hữu Vĩnh Vũ, Shun Lü, Kye Young Lee, Guzel Mukhametshina, Charuwan Akewanlop, Filippo de Marinis, Laura Bonanno, Manuel Dómine, Frances A. Shepherd, Damien Urban, Xiangning Huang, Ana Bolanos, Marta Stachowiak, Masahiro Tsuboi